These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 16033133)

  • 1. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study.
    Abry E; Thomassen IØ; Salvesen ØO; Torp SH
    Pathol Res Pract; 2010 Dec; 206(12):810-5. PubMed ID: 20951502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
    Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
    Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas.
    Torp SH; Lindboe CF; Granli US; Moen TM; Nordtømme T
    Clin Neuropathol; 2001; 20(5):190-5. PubMed ID: 11594503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
    Korshunov AG; Shishkina LV; Golanov AV
    Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
    Devaprasath A; Chacko G
    Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies].
    Miyagami M; Shibuya T; Miyagi A; Tsubokawa T
    No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
    Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
    Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry.
    Nakaguchi H; Fujimaki T; Matsuno A; Matsuura R; Asai A; Suzuki I; Sasaki T; Kirino T
    Cancer; 1999 May; 85(10):2249-54. PubMed ID: 10326705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
    Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
    Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIB-1 staining index and peritumoral brain edema of meningiomas.
    Ide M; Jimbo M; Yamamoto M; Umebara Y; Hagiwara S; Kubo O
    Cancer; 1996 Jul; 78(1):133-43. PubMed ID: 8646709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
    Miyagami M; Kanou T; Nakamura S
    No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S100A5: a marker of recurrence in WHO grade I meningiomas.
    Hancq S; Salmon I; Brotchi J; De Witte O; Gabius HJ; Heizmann CW; Kiss R; Decaestecker C
    Neuropathol Appl Neurobiol; 2004 Apr; 30(2):178-87. PubMed ID: 15043715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study.
    Loussouarn D; Brunon J; Avet-Loiseau H; Campone M; Mosnier JF
    Hum Pathol; 2006 Apr; 37(4):415-21. PubMed ID: 16564915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
    Kärjä V; Sandell PJ; Kauppinen T; Alafuzoff I
    Hum Pathol; 2010 Feb; 41(2):199-207. PubMed ID: 19801161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
    Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
    Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.